What are the best outcome measurements for atopic eczema? A systematic review

结果(博弈论) 医学 系统回顾 皮肤病科 梅德林 经济 生物 生物化学 数理经济学
作者
Jochen Schmitt,Sinéad Langan,Hywel C Williams
出处
期刊:The Journal of Allergy and Clinical Immunology [Elsevier]
卷期号:120 (6): 1389-1398 被引量:335
标识
DOI:10.1016/j.jaci.2007.08.011
摘要

Valid and reliable outcome measurements are a prerequisite for evidence-based practice. The comparative validity and reliability of outcome measurements for assessing atopic eczema (AE) severity is unclear.We sought to assess the validity, reliability, sensitivity to change, and ease of use of outcome measurements for AE. We also sought to give recommendations on which outcomes to use in clinical research and for clinical monitoring.We performed a systematic review and survey of clinical experts and patients.Twenty published outcome measurements were identified. There is evidence of adequate construct validity for 3 measurements (Severity Scoring of Atopic Dermatitis index [SCORAD], Eczema Area and Severity Index [EASI], and Three Item Severity Score), adequate internal consistency of 1 scale (Patient-oriented Eczema Measure [POEM]), adequate interobserver reliability of 5 measurements (Basic Clinical Scoring System; Nottingham Eczema Severity Score; Objective Severity Assessment of Atopic Dermatitis; Six Area, Six Sign Atopic Dermatitis severity score; and SCORAD), adequate test-retest reliability of 1 scale (POEM), and adequate sensitivity to change of 3 measurements (EASI, SCORAD, and Investigators' Global Atopic Dermatitis Assessment). Most outcome measurements have adequate content validity, as assessed by patients and experts. Data on the time to perform the assessment was identified for 8 outcome measurements. Only SCORAD, EASI, and POEM have been tested sufficiently and performed adequately.There are too many published outcome measures for AE. Most have not been tested properly or perform adequately when tested, and their continued use hampers scientific communication.Only SCORAD, EASI, and POEM currently perform adequately. These scales should be used in future studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐乐应助deng采纳,获得10
刚刚
丘比特应助2317659604采纳,获得10
1秒前
rightme发布了新的文献求助10
7秒前
9秒前
DrW先生完成签到,获得积分10
10秒前
zhang完成签到,获得积分20
10秒前
11秒前
deng完成签到,获得积分10
12秒前
是草莓发布了新的文献求助10
14秒前
2317659604发布了新的文献求助10
15秒前
deng发布了新的文献求助10
15秒前
日出完成签到,获得积分10
16秒前
Lylex应助科研通管家采纳,获得10
23秒前
CharlotteBlue应助科研通管家采纳,获得30
23秒前
完美世界应助科研通管家采纳,获得10
23秒前
研友_VZG7GZ应助科研通管家采纳,获得10
23秒前
23秒前
深情安青应助科研通管家采纳,获得50
23秒前
YzD应助科研通管家采纳,获得10
23秒前
乐乐应助科研通管家采纳,获得10
23秒前
23秒前
FashionBoy应助百事可乐可口采纳,获得10
26秒前
默11完成签到 ,获得积分10
28秒前
酷酷念瑶完成签到 ,获得积分10
33秒前
yanzi完成签到,获得积分10
34秒前
香蕉觅云应助Turew采纳,获得10
35秒前
36秒前
LOVER完成签到 ,获得积分10
37秒前
37秒前
38秒前
monstar完成签到,获得积分20
38秒前
淡然觅海发布了新的文献求助10
39秒前
Akim应助小小鱼采纳,获得10
41秒前
快乐访旋发布了新的文献求助10
42秒前
gjww应助hzbzh采纳,获得10
43秒前
优秀爆米花完成签到,获得积分20
44秒前
情怀应助快乐访旋采纳,获得10
50秒前
JIN完成签到,获得积分20
59秒前
小二郎应助是草莓采纳,获得10
59秒前
1分钟前
高分求助中
The three stars each: the Astrolabes and related texts 1100
Berns Ziesemer - Maos deutscher Topagent: Wie China die Bundesrepublik eroberte 500
Stephen R. Mackinnon - Chen Hansheng: China’s Last Romantic Revolutionary (2023) 500
Psychological Warfare Operations at Lower Echelons in the Eighth Army, July 1952 – July 1953 400
宋、元、明、清时期“把/将”字句研究 300
Julia Lovell - Maoism: a global history 300
转录因子AP-1抑制T细胞抗肿瘤免疫的机制 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2433543
求助须知:如何正确求助?哪些是违规求助? 2115625
关于积分的说明 5367896
捐赠科研通 1843729
什么是DOI,文献DOI怎么找? 917542
版权声明 561577
科研通“疑难数据库(出版商)”最低求助积分说明 490759